Poxel’s Pioglitazone Formulation Meets Key Endpoints In Phase II NASH Study

 
• By Joseph Haas
  
Tough choice
Poxel now must make a decision on which Phase II NASH drug to take forward • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D